Method for the Diagnosis of Aspirin Intolerance

• US 20080293047A1
• Filed: 10/17/2005
• Published: 11/27/2008
• Est. Priority Date: 10/19/2004
• Status: Abandoned Application

• Current Assignee: Biomerieux B.V. (Compagnie Merieux Alliance SAS)
• Original Assignee: Biomerieux B.V. (Compagnie Merieux Alliance SAS)
• Inventors: Pachot, Alexandre, Van Ganse, Eric, Devouassoux, Gilles, Pacheco, Yves
• Application Number:
  US11/663,211
• Publication Number:
  US 20080293047A1
• Time in Patent Office: Days
• US Class Current: 435/6.11
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates to a method for the diagnosis of aspirin intolerance based on a biological sample from a patient, characterized in that it comprises the following steps:

• • a. biological material is extracted from the biological sample,
  • b. the biological material is brought into contact with at least one specific reagent chosen from the reagents specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 25;
  • c. the expression of at least one of said target genes is determined.

Claims

1. A method for the diagnosis of aspirin intolerance based on a biological sample from a patient, wherein it comprises the following steps:

a. biological material is extracted from the biological sample,

b. the biological material is brought into contact with at least one specific reagent chosen from the reagents specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 25;

c. the expression of at least one of said target genes is determined.

2. The method for the diagnosis of aspirin intolerance as claimed in claim 1, wherein the biological sample taken from the patient is a blood sample.

3. The method as claimed in claim 1, wherein the biological material extracted in step a) comprises nucleic acids.

4. The method as claimed in claim 3, wherein the at least one specific reagent of step b) comprises at least one hybridization probe.

5. The method as claimed in claim 4, wherein the at least one hybridization probe is immobilized on a support.

6. The method as claimed in claim 1, wherein, in step b), the biological material is brought into contact with at least 25 specific reagents chosen from the reagents specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 25, and the expression of at least 25 of said target genes is determined in step c.

7. The method as claimed in claim 1, wherein, in step b), the biological material is brought into contact with at least 17 specific reagents chosen from the reagents specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 6;

8;

11 to 12;

15 to 19;

22 to 23 and 25, and the expression of at least 17 of said target genes is determined in step c.

8. The method as claimed in claim 1, wherein, in step b), the biological material is brought into contact with at least 19 specific reagents chosen from the reagents specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 10;

13 to 15;

17 to 21;

24, and the expression of at least 19 of said target genes is determined in step c.

9. The method as claimed in claim 1, wherein, in step b), the biological material is brought into contact with at least 11 specific reagents chosen from the reagents specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 6;

8;

15;

17 to 19, and the expression of at least 10 of said target genes is determined in step c.

10. A substrate comprising at least one hybridization probe specific for at least one target gene exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 25.

16. A kit for diagnosing aspirin intolerance, comprising a substrate as claimed in claim 10.

11. A substrate comprising at least 25 hybridization probes chosen from the probes specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 25.

12. A substrate comprising at least 17 hybridization probes chosen from the probes specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 6;

8;

11 to 12;

15 to 19;

22 to 23 and 25.

13. A substrate comprising at least 19 hybridization probes chosen from the probes specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 10;

13 to 15;

17 to 21;

24.

14. A substrate comprising at least 11 hybridization probes chosen from the probes specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 6;

8;

15;

17 to 19.

15. (canceled)